P
Prashant P. Deshpande
Researcher at Bristol-Myers Squibb
Publications - 35
Citations - 1095
Prashant P. Deshpande is an academic researcher from Bristol-Myers Squibb. The author has contributed to research in topics: Claisen rearrangement & Pyran. The author has an hindex of 9, co-authored 35 publications receiving 1033 citations. Previous affiliations of Prashant P. Deshpande include AstraZeneca.
Papers
More filters
Journal ArticleDOI
Discovery of Dapagliflozin: A Potent, Selective Renal Sodium-Dependent Glucose Cotransporter 2 (SGLT2) Inhibitor for the Treatment of Type 2 Diabetes
Wei Meng,Bruce A. Ellsworth,Alexandra A. Nirschl,P.J. McCann,Manorama Patel,Ravindar N. Girotra,Gang Wu,Philip M. Sher,Eamonn P. Morrison,Scott A. Biller,Robert Zahler,Prashant P. Deshpande,Annie Pullockaran,Deborah Hagan,Nathan Morgan,Joseph R. Taylor,Mary T. Obermeier,William G. Humphreys,Ashish Khanna,Lorell Discenza,James G. Robertson,Aiying Wang,Songping Han,John R. Wetterau,Evan B. Janovitz,Oliver P. Flint,Jean M. Whaley,William N. Washburn +27 more
TL;DR: The C-aryl glucoside 6 (dapagliflozin) was identified as a potent and selective hSGLT2 inhibitor which reduced blood glucose levels in a dose-dependent manner by as much as 55% in hyperglycemic streptozotocin (STZ) rats.
Patent
Methods of producing c-aryl glucoside sglt2 inhibitors
Prashant P. Deshpande,Bruce A. Ellsworth,Janak Singh,Theodor Denzel,Chiajen Lai,Gerard A. Crispino,Michael E. Randazzo,Jack Z. Gougoutas +7 more
TL;DR: In this paper, a method for the production of C-aryl glucoside SGLT2 inhibitors useful for the treatment of diabetes and related diseases is presented. But this method requires the use of amino acid complex forming reagents.
Patent
Crystalline solvates and complexes of (1s) -1, 5-anhydro-1-c- (3- ( (phenyl) methyl) phenyl) -d-glucitol derivatives with amino acids as sglt2 inhibitors for the treatment of diabetes
Jack Z. Gougoutas,Hildegard Lobinger,Srividya Ramakrishnan,Prashant P. Deshpande,Jeffrey T. Bien,Chiajen Lai,Chenchi Wang,Peter Riebel,John A. Grosso,Alexandra A. Nirschl,Janak Singh,John D. Dimarco +11 more
TL;DR: In this article, the physical crystal structures of a compound of the formula I: wherein R 1, R 2, R2a, R3 and R4 are as defined herein, especially pharmaceutical compositions containing structures of compound I or II.
Patent
Crystal structures of sglt2 inhibitors and processes for preparing same
Jack Z. Gougoutas,Hildegard Lobinger,Srividya Ramakrishnan,Prashant P. Deshpande,Jeffrey T. Bien,Chiajen Lai,Chenchi Wang,Peter Riebel,John A. Grosso,Alexandra A. Nirschl,Janak Singh,John D. Dimarco +11 more
TL;DR: In this paper, physical crystal structures of a compound of the formula I: wherein R 1, R 2, R 2a, R 3 and R 4 are as defined herein.
Journal ArticleDOI
C-Arylglucoside synthesis: triisopropylsilane as a selective reagent for the reduction of an anomeric C-phenyl ketal
Bruce A. Ellsworth,Abigail G. Doyle,Manorama Patel,Janet Caceres-Cortes,Wei Meng,Prashant P. Deshpande,Annie Pullockaran,William N. Washburn +7 more
TL;DR: Czernecki et al. as mentioned in this paper showed that triisopropylsilane as a reducing agent gives a 4:1 mixture of anomers (β:α) for tetra-O-benzyl-protected 1C-phenylglucoside.